Russell Investments Group
ABUS icon

Russell Investments Group’s Arbutus Biopharma ABUS Stock Holding History

Russell Investments Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
59,161
+36,486
+161% +$160K ﹤0.01% 3040
2026
Q1 		$102K Sell
22,675
-1,139
-5% -$4.98K ﹤0.01% 3081
2025
Q4 		$115K Buy
23,814
+1,075
+5% +$4.83K ﹤0.01% 3014
2025
Q3 		$103K Buy
22,739
+14,787
+186% +$54.3K ﹤0.01% 3016
2025
Q2 		$24.6K Sell
7,952
-914
-10% -$3.04K ﹤0.01% 3147
2025
Q1 		$30.9K Buy
8,866
+6,350
+252% +$21.2K ﹤0.01% 3012
2024
Q4 		$8.23K Sell
2,516
-2,267
-47% -$8.34K ﹤0.01% 3180
2024
Q3 		$18.4K Buy
4,783
+1,319
+38% +$5.06K ﹤0.01% 2977
2024
Q2 		$10.7K Buy
3,464
+318
+10% +$954 ﹤0.01% 3059
2024
Q1 		$8.12K Buy
3,146
+883
+39% +$2.29K ﹤0.01% 2873
2023
Q4 		$5.66K Sell
2,263
-1,840
-45% -$3.6K ﹤0.01% 2895
2023
Q3 		$8.33K Buy
4,103
+3,946
+2,513% +$8.27K ﹤0.01% 3051
2023
Q2 		$361 Sell
157
-1,187
-88% -$3.09K ﹤0.01% 3380
2023
Q1 		$4.07K Buy
+1,344
New +$3.79K ﹤0.01% 2960
2022
Q2 		– Sell
-4,120
Closed -$12K – 2872
2022
Q1 		$12K Hold
4,120
– – ﹤0.01% 2702
2021
Q4 		$16K Sell
4,120
-4,323
-51% -$16.8K ﹤0.01% 2961
2021
Q3 		$36K Sell
8,443
-4,614
-35% -$15.4K ﹤0.01% 2964
2021
Q2 		$39K Buy
+13,057
New +$40.4K ﹤0.01% 3149
2020
Q3 		– Sell
-43,100
Closed -$78K – 3172
2020
Q2 		$78K Buy
+43,100
New +$70.5K ﹤0.01% 2929

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
CCA
Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group's ABUS Position: Q2 2026 in Review

Russell Investments Group increased its Arbutus Biopharma (ABUS) stake by 161% in Q2 2026, buying an estimated $160K and bringing the position to 59,161 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Russell Investments Group first reported a position in ABUS in Q2 2020 and has held it in 19 quarters since. 55 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Russell Investments Group held 59,161 shares of Arbutus Biopharma worth $284K as of Q2 2026.
  • Russell Investments Group bought 36,486 Arbutus Biopharma shares in Q2 2026, an estimated $160K.
  • Arbutus Biopharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3040 holding.
  • Russell Investments Group first reported a position in Arbutus Biopharma in Q2 2020 and has held it in 19 quarters since.
  • 55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.